Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of “Hold” by Brokerages

Corcept Therapeutics Incorporated (NASDAQ:CORT) has received a consensus rating of “Hold” from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $80.8333.

A number of brokerages have issued reports on CORT. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a report on Wednesday, December 31st. Canaccord Genuity Group lowered their price objective on shares of Corcept Therapeutics from $140.00 to $99.00 and set a “buy” rating for the company in a research report on Friday, January 2nd. HC Wainwright decreased their target price on Corcept Therapeutics from $145.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, January 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Finally, UBS Group assumed coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective for the company.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks Research raised its Q4 2027 EPS estimate for CORT to $1.29 from $1.12, a small upside to that specific quarter despite the firm’s overall bearish stance. Read More.
• Positive Sentiment: Zacks also nudged up its Q4 2026 EPS estimate to $0.49 from $0.43 — another isolated upward revision that could be seen as modestly supportive for near-term quarterly expectations. Read More.
• Neutral Sentiment: Coverage pieces are highlighting Corcept’s profit profile versus peers and discussing growth prospects; these help keep the company on investors’ radar but don’t change fundamentals by themselves. Read More.
• Neutral Sentiment: Industry comparisons (e.g., profitability vs. a faster-growing rival) provide context for valuation debates but are not immediate catalysts. Read More.
• Negative Sentiment: Zacks Research downgraded CORT from “hold” to a “strong sell” and trimmed several near-term and FY2027 EPS forecasts (multiple cuts to Q1–Q3 2026/2027 and a FY2027 cut to $3.21 from $3.35). The downgrade and lower multi-quarter estimates are a clear negative catalyst for sentiment and can pressure the stock. Read More.
• Negative Sentiment: Multiple law firms (Pomerantz, Schall, DJS) have announced investigations alleging potential misstatements or nondisclosures; the emergence of shareholder litigation risk typically weighs on investor sentiment and can create legal and reputational uncertainty. Read More. Read More. Read More.
• Negative Sentiment: An outside price-target cut was reported (a ~28% reduction to $92.82), which can recalibrate upside expectations and contribute to selling pressure from valuation-conscious investors. Read More.

Corcept Therapeutics Trading Down 1.9%

Shares of CORT traded down $0.66 on Friday, reaching $34.73. 2,415,758 shares of the company’s stock were exchanged, compared to its average volume of 2,755,831. The business has a 50 day moving average price of $69.09 and a two-hundred day moving average price of $72.24. Corcept Therapeutics has a 12 month low of $32.99 and a 12 month high of $117.33. The stock has a market capitalization of $3.65 billion, a P/E ratio of 39.47 and a beta of 0.23. The company has a current ratio of 3.14, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The business had revenue of $207.64 million for the quarter, compared to analyst estimates of $223.78 million. During the same period in the prior year, the firm posted $0.41 EPS. Corcept Therapeutics’s revenue was up 13.8% on a year-over-year basis. Research analysts anticipate that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, CEO Joseph K. Belanoff sold 40,000 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.77, for a total transaction of $3,190,800.00. Following the completion of the transaction, the chief executive officer owned 2,701,370 shares in the company, valued at approximately $215,488,284.90. This represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $79.53, for a total value of $397,650.00. Following the completion of the sale, the insider directly owned 10,277 shares in the company, valued at $817,329.81. This represents a 32.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 194,500 shares of company stock worth $14,186,410 over the last three months. 20.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC boosted its position in Corcept Therapeutics by 546.9% during the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after acquiring an additional 1,274,215 shares during the last quarter. Norges Bank acquired a new position in Corcept Therapeutics during the second quarter worth $72,048,000. TD Asset Management Inc grew its position in Corcept Therapeutics by 16.6% in the third quarter. TD Asset Management Inc now owns 956,136 shares of the biotechnology company’s stock valued at $79,464,000 after purchasing an additional 136,254 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Corcept Therapeutics by 223.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock valued at $70,632,000 after buying an additional 587,053 shares during the last quarter. Finally, Epoch Investment Partners Inc. lifted its position in Corcept Therapeutics by 10.7% during the 3rd quarter. Epoch Investment Partners Inc. now owns 847,104 shares of the biotechnology company’s stock worth $70,403,000 after buying an additional 81,700 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.